Beyond the Scale: Emerge Weight Loss Expands GLP-1 Telehealth Care to Support Women Living With PCOS and Endometriosis
As emerging research illuminates tirzepatide's metabolic and anti-inflammatory effects, Emerge extends compassionate, medically supervised weight loss care from board-certified providers to women whose health needs reach far beyond a number on the scale.
Miami, FL, September 02, 2026 --(PR.com)-- For too many women, the path to being believed has been longer than the path to a diagnosis. Years of fatigue dismissed as stress. Chronic pain explained away as something to be endured. A body that seemed to work against them, and a healthcare system that too often shrugged. For women living with polycystic ovary syndrome (PCOS) and endometriosis — two conditions that together affect millions — that experience has been the rule rather than the exception.
Emerge Weight Loss (EmergeWeight.com) is working to change that. The medically supervised telehealth weight loss provider today announced that it is broadening access to its GLP-1 care program for women managing PCOS and endometriosis, recognizing what these patients have known all along: that conditions rooted in metabolic dysfunction, insulin resistance, and chronic inflammation deserve care that looks beyond weight alone.
"We kept hearing the same thing from women who came to us," said Dr. Sheryl Ashberg, Medical Director of Emerge Weight Loss. "They weren’t only asking for help with weight. They were asking to be heard — about the inflammation, the exhaustion, the cycles that never made sense. We built Emerge so that no one with a real need would be turned away. Tirzepatide goes far beyond weight loss, and so does our responsibility to the people who trust us."
PCOS and Endometriosis: Conditions That Have Long Been Misunderstood
PCOS and endometriosis are among the most common health conditions affecting women of reproductive age, each estimated to touch roughly one in ten. Yet both remain frequently underdiagnosed and undertreated.
In May 2026, a global coalition of medical organizations formally renamed PCOS as polyendocrine metabolic ovarian syndrome (PMOS) — a landmark change meant to reflect that the condition is not merely gynecological, but a complex endocrine and metabolic disorder. Insulin resistance plays a central role in PCOS: research suggests that as many as 70 percent of women with the condition experience some degree of insulin resistance, which can drive elevated androgen levels, irregular menstrual cycles, weight gain, and stubborn metabolic symptoms.
Endometriosis, in which tissue similar to the uterine lining grows outside the uterus, is increasingly understood not simply as a hormonal disorder but as a chronic inflammatory and systemic one — a condition defined by pelvic pain, fatigue, and an immune environment that keeps the body in a state of low-grade inflammation.
What the two conditions share is significant. Both are intertwined with metabolic health and chronic inflammation. And both have left countless women searching for whole-person care that treats the root causes rather than a single symptom.
Why Tirzepatide Matters Beyond Weight Loss
Tirzepatide — the active medication in therapies prescribed for type 2 diabetes and chronic weight management — is a dual GLP-1/GIP receptor agonist, meaning it works on two key metabolic pathways at once. In doing so, it improves the body’s insulin sensitivity, an effect that reaches into the heart of what makes PCOS so difficult to manage. By helping to lower circulating insulin, tirzepatide may, in turn, reduce the ovarian androgen production that fuels many PCOS symptoms, from irregular cycles to weight gain.
The real-world evidence is striking. In data presented at ObesityWeek 2025, more than 4,200 women with PCOS treated with tirzepatide achieved remarkable results: over 90 percent reached at least a 10 percent reduction in body weight within ten months — a threshold that research has linked to the return of regular ovulation in a meaningful number of patients.
Just as compelling is what scientists are learning about inflammation. A growing body of 2025 research describes the anti-inflammatory effects of GLP-1 medications as partially independent of weight loss — meaning the benefit is not simply a byproduct of a smaller body, but of the medication’s direct signaling within immune and metabolic tissue. Studies have observed reductions in inflammatory markers such as C-reactive protein, interleukin-6, and TNF-alpha — the same drivers implicated in the chronic inflammation of endometriosis. Researchers have also noted that GLP-1 receptors appear in reproductive tissue itself, including the ovaries and uterus, pointing to mechanisms that may extend well beyond appetite and metabolism.
A Measured, Medically Responsible Approach to GLP-1 Care
Tirzepatide is not FDA-approved as a treatment for PCOS or endometriosis, and the evidence connecting it to symptom relief in these conditions, while genuinely encouraging, is still emerging. What is well established is that many women with PCOS and endometriosis also live with the insulin resistance, metabolic strain, and chronic inflammation that medically supervised GLP-1 care is designed to address. Increasingly, women themselves are reporting improvements that reach beyond weight — less inflammation, steadier energy, and a greater sense of control over their bodies.
At Emerge, every patient is evaluated by board-certified medical providers, and treatment decisions are made individually, with full transparency and ongoing clinical supervision. Results vary from person to person. The commitment that does not vary is the one at the center of the company’s model: that women whose needs go beyond the scale should not be turned away.
Care That Comes From Lived Experience
That commitment is personal for the people who deliver it. Savannah Regensburger, a clinical nutritionist at Emerge Weight Loss, brings to her work not only clinical training but lived experience: she manages both endometriosis and PCOS herself.
"I spent years being told my symptoms were normal — the fatigue, the pain, the inflammation that never seemed to have an explanation anyone took seriously," Regensburger said. "Living with both endometriosis and PCOS means navigating a healthcare system that was not built with you in mind. When I started tirzepatide, what shifted was not just my weight. It was my energy, my inflammation, my sense of finally understanding what my body had been trying to tell me for years. These are not fringe conditions. They are conditions that have been dismissed for decades, and women deserve access to care that actually meets them where they are."
Her perspective reflects the heart of the Emerge model, which pairs weight loss medication with the kind of holistic support that lasting wellness requires: personalized nutrition guidance, mental health support, and the community and accountability of Emerge Wellness Sessions (EWS), where patients find encouragement alongside expert care.
"What I see over and over again is women who have been reduced to a single data point — a number on a scale, a hormone panel, a diagnosis that gets treated in isolation," she added. "Endometriosis and PCOS are systemic conditions. They live in inflammation, in metabolic dysfunction, in the way a body absorbs nutrients and processes stress. Medication can be a powerful tool, but it works best when it is paired with nutrition support, with education, with a care team that sees the whole person. That is the standard women with these conditions have always deserved, and it is the standard Emerge is committed to."
A Telehealth Model Built on Care, Compassion, and Community
Emerge’s expansion into PCOS and endometriosis support is less a new direction than a deepening of the philosophy the company was founded on. Through accessible telehealth appointments, dedicated medical oversight, and straightforward pricing with no hidden costs, Emerge has worked to remove the barriers that keep women from the weight loss and wellness care they need. Its programs extend beyond the prescription to address the whole person — nutrition, mental health, inflammation, and the sense of belonging that turns a treatment plan into a sustainable way of living.
Women who want to learn more about Emerge’s approach to GLP-1 care for PCOS and related conditions can visit EmergeWeight.com/PCOS.
Looking Forward
The story of GLP-1 medicine is still being written, and Emerge intends to write its chapter with both ambition and integrity — following the science, listening to its community, and refusing to let any woman feel invisible inside her own care. Because the measure of medicine has never been a number on a scale. It is whether a person feels seen, supported, and finally well.
About Emerge Weight Loss
Emerge Weight Loss is a medically supervised telehealth weight loss provider dedicated to compassionate, whole-person wellness. Through access to board-certified medical providers, transparent pricing, and personalized GLP-1 care, Emerge helps patients pursue sustainable health with dignity and support. Beyond medication, Emerge offers nutrition guidance, mental health support, and community connection through Emerge Wellness Sessions (EWS) and the Emerge Together community — because lasting wellness is built on care, accountability, and belonging. Learn more at EmergeWeight.com.
Emerge Weight Loss (EmergeWeight.com) is working to change that. The medically supervised telehealth weight loss provider today announced that it is broadening access to its GLP-1 care program for women managing PCOS and endometriosis, recognizing what these patients have known all along: that conditions rooted in metabolic dysfunction, insulin resistance, and chronic inflammation deserve care that looks beyond weight alone.
"We kept hearing the same thing from women who came to us," said Dr. Sheryl Ashberg, Medical Director of Emerge Weight Loss. "They weren’t only asking for help with weight. They were asking to be heard — about the inflammation, the exhaustion, the cycles that never made sense. We built Emerge so that no one with a real need would be turned away. Tirzepatide goes far beyond weight loss, and so does our responsibility to the people who trust us."
PCOS and Endometriosis: Conditions That Have Long Been Misunderstood
PCOS and endometriosis are among the most common health conditions affecting women of reproductive age, each estimated to touch roughly one in ten. Yet both remain frequently underdiagnosed and undertreated.
In May 2026, a global coalition of medical organizations formally renamed PCOS as polyendocrine metabolic ovarian syndrome (PMOS) — a landmark change meant to reflect that the condition is not merely gynecological, but a complex endocrine and metabolic disorder. Insulin resistance plays a central role in PCOS: research suggests that as many as 70 percent of women with the condition experience some degree of insulin resistance, which can drive elevated androgen levels, irregular menstrual cycles, weight gain, and stubborn metabolic symptoms.
Endometriosis, in which tissue similar to the uterine lining grows outside the uterus, is increasingly understood not simply as a hormonal disorder but as a chronic inflammatory and systemic one — a condition defined by pelvic pain, fatigue, and an immune environment that keeps the body in a state of low-grade inflammation.
What the two conditions share is significant. Both are intertwined with metabolic health and chronic inflammation. And both have left countless women searching for whole-person care that treats the root causes rather than a single symptom.
Why Tirzepatide Matters Beyond Weight Loss
Tirzepatide — the active medication in therapies prescribed for type 2 diabetes and chronic weight management — is a dual GLP-1/GIP receptor agonist, meaning it works on two key metabolic pathways at once. In doing so, it improves the body’s insulin sensitivity, an effect that reaches into the heart of what makes PCOS so difficult to manage. By helping to lower circulating insulin, tirzepatide may, in turn, reduce the ovarian androgen production that fuels many PCOS symptoms, from irregular cycles to weight gain.
The real-world evidence is striking. In data presented at ObesityWeek 2025, more than 4,200 women with PCOS treated with tirzepatide achieved remarkable results: over 90 percent reached at least a 10 percent reduction in body weight within ten months — a threshold that research has linked to the return of regular ovulation in a meaningful number of patients.
Just as compelling is what scientists are learning about inflammation. A growing body of 2025 research describes the anti-inflammatory effects of GLP-1 medications as partially independent of weight loss — meaning the benefit is not simply a byproduct of a smaller body, but of the medication’s direct signaling within immune and metabolic tissue. Studies have observed reductions in inflammatory markers such as C-reactive protein, interleukin-6, and TNF-alpha — the same drivers implicated in the chronic inflammation of endometriosis. Researchers have also noted that GLP-1 receptors appear in reproductive tissue itself, including the ovaries and uterus, pointing to mechanisms that may extend well beyond appetite and metabolism.
A Measured, Medically Responsible Approach to GLP-1 Care
Tirzepatide is not FDA-approved as a treatment for PCOS or endometriosis, and the evidence connecting it to symptom relief in these conditions, while genuinely encouraging, is still emerging. What is well established is that many women with PCOS and endometriosis also live with the insulin resistance, metabolic strain, and chronic inflammation that medically supervised GLP-1 care is designed to address. Increasingly, women themselves are reporting improvements that reach beyond weight — less inflammation, steadier energy, and a greater sense of control over their bodies.
At Emerge, every patient is evaluated by board-certified medical providers, and treatment decisions are made individually, with full transparency and ongoing clinical supervision. Results vary from person to person. The commitment that does not vary is the one at the center of the company’s model: that women whose needs go beyond the scale should not be turned away.
Care That Comes From Lived Experience
That commitment is personal for the people who deliver it. Savannah Regensburger, a clinical nutritionist at Emerge Weight Loss, brings to her work not only clinical training but lived experience: she manages both endometriosis and PCOS herself.
"I spent years being told my symptoms were normal — the fatigue, the pain, the inflammation that never seemed to have an explanation anyone took seriously," Regensburger said. "Living with both endometriosis and PCOS means navigating a healthcare system that was not built with you in mind. When I started tirzepatide, what shifted was not just my weight. It was my energy, my inflammation, my sense of finally understanding what my body had been trying to tell me for years. These are not fringe conditions. They are conditions that have been dismissed for decades, and women deserve access to care that actually meets them where they are."
Her perspective reflects the heart of the Emerge model, which pairs weight loss medication with the kind of holistic support that lasting wellness requires: personalized nutrition guidance, mental health support, and the community and accountability of Emerge Wellness Sessions (EWS), where patients find encouragement alongside expert care.
"What I see over and over again is women who have been reduced to a single data point — a number on a scale, a hormone panel, a diagnosis that gets treated in isolation," she added. "Endometriosis and PCOS are systemic conditions. They live in inflammation, in metabolic dysfunction, in the way a body absorbs nutrients and processes stress. Medication can be a powerful tool, but it works best when it is paired with nutrition support, with education, with a care team that sees the whole person. That is the standard women with these conditions have always deserved, and it is the standard Emerge is committed to."
A Telehealth Model Built on Care, Compassion, and Community
Emerge’s expansion into PCOS and endometriosis support is less a new direction than a deepening of the philosophy the company was founded on. Through accessible telehealth appointments, dedicated medical oversight, and straightforward pricing with no hidden costs, Emerge has worked to remove the barriers that keep women from the weight loss and wellness care they need. Its programs extend beyond the prescription to address the whole person — nutrition, mental health, inflammation, and the sense of belonging that turns a treatment plan into a sustainable way of living.
Women who want to learn more about Emerge’s approach to GLP-1 care for PCOS and related conditions can visit EmergeWeight.com/PCOS.
Looking Forward
The story of GLP-1 medicine is still being written, and Emerge intends to write its chapter with both ambition and integrity — following the science, listening to its community, and refusing to let any woman feel invisible inside her own care. Because the measure of medicine has never been a number on a scale. It is whether a person feels seen, supported, and finally well.
About Emerge Weight Loss
Emerge Weight Loss is a medically supervised telehealth weight loss provider dedicated to compassionate, whole-person wellness. Through access to board-certified medical providers, transparent pricing, and personalized GLP-1 care, Emerge helps patients pursue sustainable health with dignity and support. Beyond medication, Emerge offers nutrition guidance, mental health support, and community connection through Emerge Wellness Sessions (EWS) and the Emerge Together community — because lasting wellness is built on care, accountability, and belonging. Learn more at EmergeWeight.com.
Contact
Emerge Weight Loss, LLC
Lauren Calendrillo
(305) 930-7387
emergeweight.com
Lauren Calendrillo
(305) 930-7387
emergeweight.com
Contact
Categories